US03836J2015 - Common Stock
APREA THERAPEUTICS INC
NASDAQ:APRE (5/6/2024, 7:00:00 PM)
After market: 5.31 +0.05 (+0.95%)5.26
-0.09 (-1.68%)
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-10-03. The company is focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. Its synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DDR. The company is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Its lead WEE1 inhibitor product candidate is ATRN-1051. In addition, it has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. The company is also evaluating combination opportunities within its pipeline, including research on the combination of ATRN-119 and ATRN-1051. Its pipeline includes the clinical-stage asset ATRN-119, an ATR inhibitor that is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid tumors having mutations in defined DDR-related genes.
APREA THERAPEUTICS INC
3805 OLD EASTON ROAD
Doylestown PENNSYLVANIA 02116
P: 16174639385
CEO: Christian S. Schade
Employees: 9
Website: https://www.aprea.com/
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation...
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for...
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Here you can normally see the latest stock twits on APRE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: